-
Dr. Reddy’s Laboratories Reports 9% YOY Revenue Growth in Q2 2024 Fiscal Year
•
India-based generics giant Dr. Reddy’s Laboratories Ltd (NYSE: RDY) has released its financial report for the Q2 2024 fiscal year ended September 30, 2023. The company reported consolidated revenues of USD 828 million for the quarter, marking a 9% year-on-year (YOY) increase. This growth was primarily driven by robust generic…
-
Jenscare Scientific’s Ken Valve Enters NMPA Priority Review for Aortic Valve System
•
Jenscare Scientific Co., Ltd (HKG: 9877), a leading structural heart disease device manufacturer based in Ningbo, has announced that its regulatory filing for the transcatheter artificial aortic valve system, Ken Valve, has been accepted into the priority review process by the National Medical Products Administration (NMPA). This marks a significant…
-
Alphamab Oncology and 3D Medicines Gain FDA Approval for Envafolimab Phase III Trial
•
Partners Alphamab Oncology (HKG: 9966) and 3D Medicines (HKG: 1244) have announced that they have received approval from the US Food and Drug Administration (FDA) to conduct a Phase III clinical study for envafolimab (KN035) in proficient mismatch repair (fMMR) advanced or recurrent endometrial cancer combined with lenvatinib. This approval…
-
China Grand Pharma’s Lava Liquid Embolic Agent Officially Commercialized in the US
•
China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has announced the official commercialization of its subsidiary BlackSwan Vascular, Inc.’s innovative liquid embolic agent, Lava, in the United States. This marks a significant milestone for the company as it expands its presence in the US medical market. US Market…
-
Mindray Bio-Medical Electronics Posts Strong Q1-Q3 2023 Financial Results
•
Shenzhen Mindray Bio-Medical Electronics Co., Ltd (SHE: 300760) has revealed a robust financial performance for the Q1-Q3 2023 period. The company generated RMB 27.3 billion (USD 3.74 billion) in revenues during the first three quarters, marking a 17.2% year-on-year (YOY) increase. This growth underscores Mindray’s strong market position and effective…
-
Fosun Pharma Gains NMPA Approval for Clinical Trials of HLX42 and HLX43 ADCs
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) has announced that it has received approval from the National Medical Products Administration (NMPA) in China to conduct separate clinical studies for HLX42 and HLX43. These two pipeline candidates are antibody drug conjugates (ADCs) co-developed by subsidiary Shanghai Henlius Biotech Inc., (HKG:…
-
Innovent Biologics’ Mazdutide Shows Promising Weight Loss Results in Phase II Trial
•
China-based Innovent Biologics Inc., (HKG: 1801) has revealed compelling Phase II data for its weight loss drug candidate, mazdutide (IBI362), after 48 weeks of treatment. The higher dose (9mg) of mazdutide demonstrated significant efficacy in achieving weight loss among Chinese subjects with obesity, alongside favorable safety profiles and multiple metabolic…
-
Sanofi SA Reports Q3 2023 Financials with Focus on R&D and Dupixent Growth
•
French pharmaceutical giant Sanofi SA (NASDAQ: SNY) released its Q3 2023 financial results, reporting a net sales decrease of -4.1% year-on-year (YOY) but an increase of 3.2% in constant currency terms, reaching EUR 11.96 billion (USD 12.64 billion). Despite maintaining the forecast for 2023 earnings per share (EPS) growth, Sanofi…
ADC / XDC AstraZeneca Auto-immune AZ Biosimilars Biotech BMS Bristol-Myers Squibb Cancer CAR-T Cell-therapy Clinical trial approval / initiation Clinical trial results Combination therapy CRO / CMO / CDMO CVD Diabetes Eli Lilly Finance Finanical Reports Gene therapy Hengrui Medicine J&J Johnson & Johnson Market approval filings Merck MSD Multi-specific antibodies NASDAQ: AZN NMPA Novartis NYSE: BMY NYSE: JNJ NYSE: LLY NYSE: MRK NYSE: NVS Obesity Ophthalmology PD-1/L1 Potential first-in-class Product approvals Rare / orphan disease drugs SHA: 600276 TKIs (EGFR VEGF BTK etc.) Vaccine
